About US
Contact us
-
Once-spurned cancer drugs win NICE's favor with—no surprise—'sensible pricing'England’s cost-effectiveness watchdogs are a tough audience, and they've often angered cancer drugmakers when meds were turned away. Recently, however, a steady stream of oncology meds have made it th2017/1/11
-
Ex-VP sues Bayer, saying she defended a pregnant colleague and got whacked for itPreviously Bayer’s “Working Mother of the Year,” former vice president Irene Laurora has sued the Big Pharma, allegingshe was mistreatedafter she stood up for a pregnant colleague. Laurora’s lawsuit2017/1/10
-
Rest easy, pharma. AstraZeneca, Ranbaxy prevailed in landmark pay-for-delay caseIn 2013, it looked as if AstraZeneca and Ranbaxy couldface billionsin damages in a lawsuit alleging they struck an illegal deal to block a generic of the blockbuster heartburn remedy Nexium. Now that2017/1/10
-
The Top Three International Regulatory Compliance ChallengesThe challenge of complying with supply chain regulations is now greater than ever. Legislators around the world have responded to the risks posed to healthcare supply chains with new requirements. T2017/1/9
-
EpiPen maker Mylan, U.S. officials stiff-arm senator's call to testify on DOJ settlementU.S. lawmakers are still trying to hold Mylan accountable for its controversial EpiPen price hikes. But the company now flatly refuses to testify at a committee hearing convened by Sen. Charles Grassl2017/1/9
-
Who owns 'moonshot'? MD Anderson says it does in suit against biotech billionaire Soon-ShiongFor years, the University of Texas’ MD Anderson Cancer Center has used the Cancer Moonshot tagline without any challengers. That is, until two separate programs with similar names came along earlier t2017/1/6
-
Pfizer sues Texas agency for leaking 'confidential' Medicaid pricing dealsPfizer has faced scrutiny for its drug pricing over the last year, but now it’s bringing some heat of its own to protect those numbers from prying eyes. The pharma giant last week sueda Texasagency, c2017/1/6
-
Teva sets aside $520M to settle bribery investigations by DOJ, SECTeva is trying to clean the slate on its history of allegedly paying bribes in foreign countries to boost sales. Having revamped its governance programs and set a new tone about bad behavior, it has n2017/1/5
-
DOJ's price-fixing investigation could lead to sizable liabilities, analyst saysWhile industry closely tracks developments on the Department of Justice price-fixing investigation into a host of generics companies, one influential analyst has run the numbers on potential liabiliti2017/1/5
-
DOJ pricing probe threatens $1B-plus fines, but few generics makers will face charges: AnalystsNews that the Justice Department is preparing criminal charges in its long-standing investigation into generic drug pricing hit those companies hard Thursday afternoon, wiping out $8.5 billion in mark2017/1/4